Vor Biopharma (VOR) Preferred Stock Liabilities (2020)
Vor Biopharma's (VOR) quarterly Preferred Stock Liabilities came in at $42.8 million in Q4 2020, up 2139200.0% on a QoQ basis from $2000.0 in Q3 2020.
Vor Biopharma (VOR) Preferred Stock Liabilities (2020) Analysis & Trends
Vor Biopharma (VOR) has 1 years of Preferred Stock Liabilities data on file, last reported at $42.8 million in Q4 2020.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $42.8 million in Q4 2020; TTM through Dec 2020 was $42.8 million, a N/A change from a year earlier, with the FY2020 full-year figure at $42.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2020 stood at $42.8 million, up from $2000.0 in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for VOR reached as high as $64.5 million in Q2 2020 and fell as low as $2000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vor Biopharma | 187.37 Mn | 187.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 42.79 Mn |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 64.55 Mn |
| Mar 31, 2020 | 2,000.00 |